NewLink Genetics (NLNK -3.3%) slips after its Q1 misses estimates across the board this morning. Net losses grew on a decline in grant revenue and a jump in R&D expenses, primarily due to increased manufacturing and clinical trial costs. Looking at its pipeline, the company says it anticipates completing patient accrual for its Impress trial of algenpantucel-L for surgically resected pancreatic cancer, and it recently presented preclinical results for its second IDO pathway inhibitor drug candidate, NLG919, at the American Association for Cancer Research annual meeting. Based on the data, it plans to initiate clinical trials later this year.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at CNBC.com (Jan 6, 2015)
at Nasdaq.com (Jan 5, 2015)
at Benzinga.com (Dec 24, 2014)
at CNBC.com (Dec 24, 2014)
at Benzinga.com (Dec 22, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs